Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06846281 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
360
Enrollment target
20
Study locations

NCT06846281 is a Phase 3 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 360 participants, below the 2,154-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06846281, a Phase 3 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
360 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Conditions Studied

Relapsing Multiple Sclerosis

Interventions

  • DRUG Ocrelizumab
  • DRUG Remibrutinib oral treatment

Study Locations (20)

Florida

  • Neurology of Central FL Res Ctr - Altamonte Springs
  • University of Florida - Gainesville
  • Neurology Associates PA - Maitland
  • Aqualane Clinical Research - Naples
  • Tallahassee Neurological Clinic - Tallahassee

Massachusetts

  • Tufts Medical Center - Boston
  • Lahey Hospital and Medical Center - Burlington
  • Neurology Center of New England PC - Foxborough

Michigan

  • Michigan Institute of Neurological - Farmington Hills
  • Memorial HC Ins for Neuroscience - Owosso

Arizona

  • Perseverance Research Center - Scottsdale

District of Columbia

  • Medstar Washington Hospital Center - Washington D.C.

Illinois

  • Rush University Medical Center - Chicago

Kansas

  • University of Kansas Hospital - Kansas City

Maryland

  • MedStar Montgomery Medical Center - Olney

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2025-07-23
Est. Completion 2031-06-20
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06846281

The ClinicalTrials.gov registry entry for NCT06846281 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,154-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (83% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab is the first listed.

NCT06846281 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT06846281 about?

NCT06846281 is a clinical study titled "Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.". The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

What is the current status of trial NCT06846281?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2025-07-23. Estimated completion is 2031-06-20.

What conditions does trial NCT06846281 study?

This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.

What interventions are being tested in trial NCT06846281?

The interventions under investigation include: Ocrelizumab (DRUG), Remibrutinib oral treatment (DRUG).

Who is sponsoring clinical trial NCT06846281?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06846281 being conducted?

This trial has 20 study locations across Arizona, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Multiple Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.